Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four decades. Standard treatment relies on DNA dama...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/31262 |